GLP-1 Companion · Research

Is Foundayo Approved in the EU? What the CHMP Opinion Means

Is Foundayo Approved in the EU? What the CHMP Opinion Means
TL;DR

Not yet. On 15 October 2026 the European Medicines Agency's CHMP recommended an EU marketing authorisation for Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 tablet, for weight management and type 2 diabetes in adults. The European Commission makes the binding decision, normally within 67 days of receiving the opinion, and as of 6 November 2026 it had not been issued. After that, each country decides price and reimbursement, so access will arrive country by country. Foundayo can be taken at any time of day, with or without food, and its most common side effects are digestive.

Not yet. On 15 October 2026, the European Medicines Agency’s human medicines committee (CHMP) recommended an EU marketing authorisation for orforglipron (Foundayo), Eli Lilly’s once-daily GLP-1 tablet, for weight management and type 2 diabetes in adults.1 The European Commission still has to make the final decision.

The CHMP opinion is a scientific recommendation. The legal decision comes from the Commission, and after that each country decides what the tablet costs and whether public insurance pays. For how fiber fits with GLP-1 medicines in general, see our complete guide to fiber and GLP-1 medications.

What did the CHMP recommend?

The committee recommended Foundayo for two uses in adults.1

Weight management. For adults with a body mass index (BMI) of 30 or more, or 27 to under 30 with at least one weight-related health problem such as prediabetes, type 2 diabetes, high blood pressure, abnormal blood fats, obstructive sleep apnoea or heart disease. It is used alongside a healthy diet and physical activity, for losing weight and for keeping it off.

Type 2 diabetes. For adults whose blood sugar is not well controlled, on its own when metformin is not suitable, or together with other diabetes medicines.

Foundayo will come as film-coated tablets in six strengths: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. Treatment starts on the lowest dose and steps up gradually, depending on how well a person responds and tolerates it.1 It is prescription-only.2

The recommendation rests on two weight-management studies with 4,740 adults over 72 weeks, and four type 2 diabetes studies with 3,765 adults, in which Foundayo was compared with placebo, dapagliflozin or oral semaglutide.2

Is Foundayo approved in the EU yet?

No. The CHMP gives an opinion; the European Commission grants the authorisation. The EMA describes its own opinion as “an intermediary step” toward patient access.2

The Commission issues its decision within 67 days of receiving the EMA’s recommendation, and the authorisation then applies in all EU countries plus Iceland, Liechtenstein and Norway.3 We checked the EU register of authorised medicines, last updated 6 November 2026, and Foundayo was not on it.4 Counting 67 days from mid-October points to a decision around the end of 2026.

The previous oral GLP-1 for weight management was decided in less than the full 67 days. The Wegovy pill (oral semaglutide 25 mg) received its CHMP opinion on 22 May 2026 and its Commission authorisation on 14 July 2026, 53 days later.5

Status of the two oral GLP-1 pills for weight management in the EU. The Wegovy pill has a CHMP positive opinion (22 May 2026), a European Commission authorisation (14 July 2026) and published EU product information. Foundayo has a CHMP positive opinion (15 October 2026); its Commission decision and EU product information were still pending as of 6 November 2026.

EU regulatory status of the two oral GLP-1 pills for weight management, as of 6 November 2026. A filled dot means the step is done. Sources: EMA medicine pages and CHMP highlights; EU Union Register of medicinal products.

EU stepWegovy pill (oral semaglutide)Foundayo (orforglipron)
CHMP positive opinion22 May 202615 October 2026
European Commission authorisation14 July 2026Pending
Product information (SmPC) in all EU languagesPublishedAfter authorisation

When could people in Europe get Foundayo?

Authorisation alone does not make the tablet available. Once the Commission decides, price and reimbursement are set separately by each member state.2 So the date someone in Spain can fill a prescription, and whether their health system pays for it, will differ from the answer in Italy or Sweden.

For the weight-management use, some systems exclude these medicines from public cover altogether. In Germany, statutory health insurance by law does not pay for medicines whose main purpose is weight regulation or appetite suppression.6

The detailed product information, the full summary of product characteristics (SmPC), will be published in all official EU languages only after the Commission grants the authorisation.1

In the UK, the MHRA authorised Foundayo on 10 August 2026, the first authorisation in Europe. It is not yet available on the NHS, and NICE guidance on its use for overweight and obesity is expected on 27 January 2027.7 For country-by-country status of both pills, see our oral GLP-1 pills in Europe tracker.

How is Foundayo different from the Wegovy pill?

Both are once-daily GLP-1 tablets. They are different molecules with different rules for taking them.

Orforglipron is a small, non-peptide molecule, which is why it can survive being swallowed. The EMA says it “can be taken at any time of day, with or without food.”2 The UK label goes further: no food or water restriction.7

The Wegovy pill is a peptide. It has to be swallowed on an empty stomach with no more than 120 ml of plain water, followed by at least 30 minutes with no food, drinks or other medicines.5 We cover how that rule shapes the rest of the morning in our piece on the oral Wegovy fasting rule.

What side effects did the EMA report?

The most common side effects were nausea, vomiting and diarrhoea. The EMA notes they were more frequent while the dose was being increased and became less frequent over time.2

Constipation is also on the list. The UK product information rates it “very common”, meaning it affects more than 1 in 10 people, alongside nausea and diarrhoea.7 It is the same digestive pattern seen with the injected GLP-1 medicines, which we compared in GLP-1 pills reach Europe.

Because Foundayo has no fasting window, fiber can go at any time of day. The one habit worth keeping is to leave about 30 to 60 minutes between a large dose of gel-forming fiber, such as psyllium, and any tablet, because it can slow how a medicine taken at the same moment is absorbed.8 Our guide to taking fiber with orforglipron sets out the timing. If constipation is severe, painful or comes with vomiting, speak to the prescriber.

The next step is the Commission’s decision, expected around the end of 2026.

Frequently asked questions

Has Foundayo received EU approval? Not yet. The EMA’s medicines committee (CHMP) recommended approval on 15 October 2026. The legally binding decision belongs to the European Commission, which normally decides within 67 days of receiving the opinion. As of 6 November 2026, Foundayo was not yet listed in the EU register of authorised medicines.

When will Foundayo be available in Europe? In two steps. First the European Commission has to grant the marketing authorisation, which on the usual 67-day timeline points to around the end of 2026. Then each country sets its own price and decides whether public insurance pays, so availability and coverage will differ from country to country. In the UK, the MHRA authorised it on 10 August 2026, but it is not yet on the NHS.

What is Foundayo recommended for in the EU? For weight management in adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related health problem, alongside diet and physical activity. And for adults with type 2 diabetes that is not well controlled, either alone when metformin is not suitable or with other diabetes medicines.

Is Foundayo the same as the Wegovy pill? No. Foundayo (orforglipron, Eli Lilly) and the Wegovy pill (oral semaglutide, Novo Nordisk) are different molecules. The Wegovy pill must be taken on an empty stomach followed by a 30-minute fast. Foundayo can be taken at any time of day, with or without food. The Wegovy pill was authorised in the EU on 14 July 2026.

Footnotes

  1. European Medicines Agency, Foundayo: opinion, medicine page EMEA/H/C/006632 and CHMP summary of positive opinion EMA/CHMP/229918/2026 (opinion adopted 15 October 2026, published 16 October 2026). Applicant Eli Lilly Nederland B.V.; strengths 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg film-coated tablets; full indication text for weight management and type 2 diabetes. SmPC to be published in all official EU languages after the Commission decision. ↩ ↩2 ↩3 ↩4

  2. European Medicines Agency, “New oral GLP-1 medicine for weight management and type 2 diabetes,” news release, 16 October 2026. Prescription-only once-daily tablet, taken at any time of day with or without food; non-peptide molecule; two weight-management studies (4,740 adults, 72 weeks) and four type 2 diabetes studies (3,765 adults); most common side effects nausea, vomiting and diarrhoea; price and reimbursement decided by each member state after authorisation. Listed as “pending EC decision” in the CHMP meeting highlights of 12 to 15 October 2026. ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  3. European Medicines Agency, Authorisation of medicines: the European Commission issues its legally binding decision within 67 days of receipt of the EMA recommendation; the centralised authorisation is valid in all EU member states and in Iceland, Liechtenstein and Norway. ↩

  4. European Commission, Union Register of medicinal products for human use, list of active products, page dated 6 November 2026. No entry for Foundayo or orforglipron. Checked 6 November 2026. ↩

  5. European Commission marketing authorisation for oral semaglutide 25 mg (Wegovy pill) for weight management, 14 July 2026 (Commission Decision C(2026) 5102), following the CHMP positive opinion of 22 May 2026. Oral semaglutide product information: empty-stomach administration with no more than 120 ml plain water and a 30-minute wait. ↩ ↩2

  6. German Social Code Book V, § 34(1), sentence 8 (SGB V): medicines that mainly serve weight reduction, appetite suppression or regulation of body weight are excluded from statutory health insurance. gesetze-im-internet.de, checked 3 November 2026. ↩

  7. MHRA authorisation of orforglipron (Foundayo) for weight management and type 2 diabetes, 10 August 2026, the first in Europe; not currently available on the NHS; NICE guidance for overweight and obesity expected 27 January 2027 (GID-TA11650, NICE project page, checked 6 November 2026). GOV.UK press release. UK SmPC (emc, product 102527): §4.2 once daily at any time of day without food or water restriction; §4.8 constipation, nausea and diarrhoea “very common” (1 in 10 or more), with digestive effects higher during dose escalation. ↩ ↩2 ↩3

  8. UK ispaghula (psyllium) husk product information (MHRA): bulk-forming fiber can delay the absorption of other oral medicines taken at the same time, so keep them about 30 to 60 minutes apart. General prudence for any oral tablet; no orforglipron-specific fiber interaction has been reported. ↩